Strata Critical Medical, Inc. (SRTA) company profile
Close on Nov 16, 2026Market cap $479.49MP/E 10.6Yield –
About Strata Critical Medical
Transportation Services, SIC 4700
Strata Critical Medical, Inc. provides time-critical logistics and specialized clinical services to the healthcare sector in the United States. Through its Logistics segment, operating under the Trinity brand, the organization arranges air and ground transport for donor organs, surgical personnel, medical equipment, and biological samples, while also offering donor organ placement coordination. Through its Clinical segment, marketed under the Keystone brand, the company provides surgical organ recovery, organ preservation, normothermic regional perfusion, and cardiac perfusion services, alongside clinical staffing and medical equipment rentals. Its services are directly contracted by organ procurement organizations, transplant centers, and cardiovascular surgery hospitals.
The company operates nationwide across the United States. Its operations are supported by a workforce of 601 domestic employees, consisting of 327 full-time and 274 part-time personnel distributed across logistics, clinical, and administrative functions. Its ground logistics network utilizes hubs situated near customer locations, complemented by a fleet of ten company-owned fixed-wing aircraft alongside third-party transportation operators. Strata Critical Medical maintains its headquarters functions in the United States.
Summary of the business section of Strata Critical Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Strata Critical Medical, Inc.
- Founded
- 2019
- Headquarters
- New York, NY
- Address
- 666 Third Avenue, 25th Floor 10017
- Phone
- (212) 967-1009
- Website
- stratacritical.com
- Employees
- 601, Dec 31, 2025
- Industry
- Transportation Services
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, New York, New York
Stock & identifiers
- Ticker
- SRTA
- Former tickers
- BLDE until Aug 29, 2025; EXPC until May 10, 2021; EXPCU until Nov 10, 2020
- Exchange
- Nasdaq
- IPO date
- Sep 13, 2019
- Shares outstanding
- 88M, Jul 28, 2026
- Public float
- $263.90M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1779128
- CUSIP
- 092667104
- ISIN
- US0926671043
- FIGI
- BBG00Q3Q29N4
- Share class FIGI
- BBG00Q3Q2BD0
- EIN
- 84-1890381
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William A. Heyburn | Co-CEO and CFO, Director | 1,856,206 |
| Melissa M. Tomkiel | Co-CEO and General Counsel, Director | 2,244,475 |
| Scott M. Wunsch | CEO, Logistics | 1,129,241 |
| Louis R. Verdetto | CEO, Clinical Services | 1,260,328 |
| Amir Cohen | Chief Accounting Officer | 177,154 |
| Andrew Lauck | Director | 172,902 |
| Reginald Love | Director | 146,481 |
| Robert S. Wiesenthal | Director | 5,325,896 |
| William L. Cook III | Director | 97,671 |
| Edward M. Philip | Director | 265,078 |
| Eric Affeldt | Director | 581,214 |
| Susan M. Lyne | Director | 187,185 |
| Kenneth B. Lerer | Director | 196,859 |
| John Borthwick | Director | 203,977 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Melissa MTomkiel | $5.61M | $4.10M | $1.65M | $134 | – |
| FY2025 Robert Wiesenthal | $5.05M | $6.03M | $1.65M | $134 | – |
| FY2025 William AHeyburn | $5.33M | $3.67M | $1.65M | $134 | – |
| FY2024 Melissa MTomkiel | $0 | $0 | $5.77M | $119 | – |
| FY2024 Robert Wiesenthal | $9.56M | $4.32M | $5.77M | $119 | – |
| FY2024 William AHeyburn | $0 | $0 | $5.77M | $119 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| William A. Heyburn Co-Chief Executive Officer and Chief Financial Officer | $516.67K | $4.22M | $541.00K | $43.53K | $5.33M | -1% |
| Melissa M. Tomkiel Co-Chief Executive Officer and General Counsel | $533.33K | $4.48M | $559.00K | $42.22K | $5.61M | -9% |
| Amir M. Cohen Chief Accounting Officer | $375.00K | $301.86K | $221.00K | – | $897.86K | – |
| Scott M. Wunsch CEO, Logistics | $347.69K | $1.58M | $444.68K | $37.22K | $2.41M | – |
| Robert S. Wiesenthal Non-Executive Chairman of the Board and Former Chief Executive Officer | $500.00K | $2.28M | $688.00K | $1.58M | $5.05M | -47% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Sep 13, 2019
- Offer price
- $10.00
- Securities offered
- 25,000,000
- Gross proceeds
- $250.00M
- Exchange
- Nasdaq
- First trading day
- Nov 1, 2019
- First-day close
- $9.72-2.8%
- Lock-up ends (est.)
- Apr 29, 2020
“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-third of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company employed 601 employees, all of whom were located across the United States.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?